In parallel, the evaluation of PD-L1 inhibitors, such as the monoclonal antibodies Durvalumab, Atezolizumab and Avelumab, is currently ongoing in HNSCC [168]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.